Salpeter, SR, Ormiston, TM, Salpeter, EE (2004) Cardiovascular effects of β-agonists in patients with asthma and COPD: a metaanalysis.Chest125,2309-2321
Weise E. Asthma drug may boost risk of deadly asthma attacks. Available at: http://www.usatoday.com/news/health/2004–06-21-asthma-risk_x.htm. Accessed June 22, 2004.
Cornell University. Regular use of asthma drugs poses respiratory, cardiac dangers. Available at: http://www.sciencedaily.com/releases/2004/06/040618063513.htm. Accessed June 18, 2004.
Cornell University. Regular use of asthma drugs poses respiratory, cardiac dangers. Available at: http://www.medicalnewstoday.com/medicalnews.php?newsid=9604. Accessed June 18, 2004.
Celli, BR, MacNee, W Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper.Eur Respir J2004;23,932-946
Global Initiative for Chronic Obstructive Lung Disease. Objectives. Available at: http://www.goldcopd.com. Accessed July 20, 2004.
Global Initiative for Asthma (GINA), National Heart, Lung and Blood Institute (NHLBI).. Global strategy for asthma management and prevention. 2003; Global Initiative for Asthma (GINA), National Heart, Lung and Blood Institute (NHLBI). Bethesda, MD:.
National Asthma Education and Prevention Program. Executive summary of the NAEPP expert panel report: guidelines for the diagnosis and management of asthma; update on selected topics 2002. Bethesda, MD: National Institutes of Health, June 2002; NIH Publication No. 02–5075.
Florida Asthma News. Available at: http://florida.injuryboard.com/view.cfm/Topic=252. Accessed July 20, 2004.
Blomstrom-Lundqvist, C, Scheinman, MM, Aliot, EM, et al ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias: executive summary; a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Supraventricular Arrhythmias).Circulation2003;108,1871-1909
Milgrom, H, Skonner, DP, Bensch, G, et al Low-dose levalbuterol in children with asthma: safety and efficacy in comparison with placebo and racemic albuterol.J Allergy Clin Immunol2001;108,938-945
Braun, SR, Levy, SF Comparison of ipratropium bromide and albuterol in chronic obstructive pulmonary disease: a three center study.Am J Med1991;91,28S-32S
Burgess, CD, Ayson, M, Rajasingham, S, et al The extrapulmonary effects of increasing doses of formoterol in patients with asthma.Eur J Clin Pharmacol1998;54,141-147
Ferguson, GT, Funck-Brentano, C, Fisher, T, et al Cardiovascular safety of salmeterol in COPD.Chest2003;123,181-1824
Burggraaf, J, Westendorp, RGJ, in’t Veen, JCCM, et al Cardiovascular side effects of inhaled salbutamol in hypoxic asthmatic patients.Thorax2001;56,567-569
D’Urzo, AD, Chapman, KR, Cartier, A, et al Effectiveness and safety of salmeterol in nonspecialist practice settings.Chest2001;119,714-719
Spector, SL, Garza Gomez, M Dose-response effects of albuterol aerosol compared with isoproterenol and placebo aerosols: response to albuterol, isoproterenol, and placebo aerosols.J Allergy Clin Immunol1977;59,280-286
Pearlman, DS, Stricker, W, Weinstein, S, et al Inhaled salmeterol and fluticasone: a study comparing monotherapy and combination therapy in asthma.Ann Allergy Asthma Immunol1999;82,257-265
Anderson, G, Wilkins, E, Jariwalla, AG Fenoterol in asthma.Br J Dis Chest1979;73,81-84
Nathan, RA, Seltzer, JM, Kemp, JP, et al Safety of salmeterol in the maintenance treatment of asthma.Ann Allergy Asthma Immunol1995;75,243-248